Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Phase III Trials Hit 5.9M Data Points; Can Manual Review Protect Trial Integrity?

Clinical trials now collect an average of 5.9 million data points in each Phase III protocol, while many sponsors still depend on manual, periodic reviews. This mismatch can delay the detection of protocol deviations, safety signals, and data inconsistencies. As
  • News
Phase III Trials Hit 5.9M Data Points; Can Manual Review Protect Trial Integrity?

Medical Devices Registration in India in 2026: CDSCO Requirements and Approval Guide

Explore the CDSCO medical device registration pathway, including risk classification, Indian Authorized Agent requirements, Form MD-14 and Form MD-15, technical dossier preparation, common approval delays, and inspection-ready evidence under the Medical Devices Rules 2017.
  • Blog, Medical Devices
Medical device registration process in India showing CDSCO review, technical documentation, medical device classification in India, and regulatory approval requirements.

Hippocratic AI Buys Grove AI; Who Validates AI-Led Patient Screening?

Hippocratic AI acquired Grove AI in January 2026 after the startup spent two years building voice agents for clinical trial recruitment. Grove’s technology speaks with patients, collects screening information and helps match them with enrolling studies. The deal shows how
  • News
Hippocratic AI Buys Grove AI; Who Validates AI-Led Patient Screening?

Novo’s IL-6 Drug Lowered Inflammation; ZEUS Phase 3 Still Failed to Cut Heart Risk

Novo Nordisk reported that ziltivekimab failed to reduce major cardiovascular events in the Phase 3 ZEUS trial, despite lowering inflammation through IL-6 inhibition. The Denmark-based company tested the drug in more than 6,300 patients with cardiovascular disease, chronic kidney disease
  • News
Novo’s IL-6 Drug Lowered Inflammation; ZEUS Phase 3 Still Failed to Cut Heart Risk

Treasury Weighs China Biotech Curbs; Security Move Could Trigger a Hidden GMP Risk

US policymakers are debating whether the US Treasury should extend outbound investment controls to biotechnology transactions involving China. John Stanford, executive director at Incubate, warned that broad restrictions could affect licensing, investment and development partnerships as Chinese companies play a
  • News
Treasury Weighs China Biotech Curbs; Security Move Could Trigger a Hidden GMP Risk

$43 Billion China Biotech Rush; Can US Pharma Verify the CMC Evidence?

Chinese biotech licensing deals have become a major source of global drug pipelines. Pharmaceutical Executive reported more than $43 billion in licensing commitments during the first five months of 2026, while US lawmakers proposed broader scrutiny of biotechnology investments linked
  • News
$43 Billion China Biotech Rush; Can US Pharma Verify the CMC Evidence?

FDA Medical Devices Registration in 2026: 510(k), Device Listing, and Compliance Guide

Learn how FDA device registration and listing connects with classification, product codes, 510(k) pathways, FURLS records, annual renewal, and inspection readiness. The guide also explains common data gaps that can delay imports or threaten U.S. market access.
  • Blog, Medical Devices
Medical device compliance dashboard showing FDA medical device classification, product codes, FURLS device registration, 510(k) records, import checks, and establishment listing controls.

The Experiment Worked: Why Scientific Rationale Disappears Before CMC

A July 29, 2026 Pharmaceutical Technology feature by Christian Olsen examines a recurring failure in biologics R&D: systems preserve experimental results while losing the reasoning behind them. As candidates move from discovery into lead optimization, CMC and scale-up, missing context
  • News
The Experiment Worked: Why Scientific Rationale Disappears Before CMC